Weight Loss, HbA1c Reduction, and Tolerability of Cetilistat in a Randomized, Placebo‐controlled Phase 2 Trial in Obese Diabetics: Comparison With Orlistat (Xenical)

@article{Kopelman2010WeightLH,
  title={Weight Loss, HbA1c Reduction, and Tolerability of Cetilistat in a Randomized, Placebo‐controlled Phase 2 Trial in Obese Diabetics: Comparison With Orlistat (Xenical)},
  author={P. Kopelman and H. Gerrit Groot and A. Rissanen and S. Rossner and S. Toubro and R. Palmer and Rob Hallam and Andrew D Bryson and Roger I. Hickling},
  journal={Obesity},
  year={2010},
  volume={18}
}
  • P. Kopelman, H. Gerrit Groot, +6 authors Roger I. Hickling
  • Published 2010
  • Medicine
  • Obesity
  • The objective of this multicenter, randomized, double‐blind study was to determine the efficacy and safety of cetilistat and orlistat relative to placebo in obese patients with type 2 diabetes, on metformin. Following a 2‐week run‐in, patients were randomized to placebo, cetilistat (40, 80, or 120 mg three times daily), or orlistat 120 mg t.i.d., for 12 weeks. The primary endpoint was absolute change in body weight from baseline. Secondary endpoints included other measures of obesity and… CONTINUE READING
    Anti-Obesity Drugs: A Review about Their Effects and Safety
    • 338
    Safety of antiobesity drugs
    • 78
    What is the prognosis for new centrally-acting anti-obesity drugs?
    • 55
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 25 REFERENCES